CA2453566A1 - Methode et composition permettant d'inhiber l'activite de l'heparanase - Google Patents

Methode et composition permettant d'inhiber l'activite de l'heparanase Download PDF

Info

Publication number
CA2453566A1
CA2453566A1 CA002453566A CA2453566A CA2453566A1 CA 2453566 A1 CA2453566 A1 CA 2453566A1 CA 002453566 A CA002453566 A CA 002453566A CA 2453566 A CA2453566 A CA 2453566A CA 2453566 A1 CA2453566 A1 CA 2453566A1
Authority
CA
Canada
Prior art keywords
heparanase
animal
fragment
immunogen
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002453566A
Other languages
English (en)
Inventor
Peter Bohlen
Daniel Hicklin
Paul Kussie
Yiwen Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2453566A1 publication Critical patent/CA2453566A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01166—Heparanase (3.2.1.166)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)

Abstract

L'invention concerne des méthodes permettant d'inhiber l'activité de l'héparanase et de traiter différents états par administration, à un animal, d'une quantité efficace d'un immunogène sollicitant une réponse immunitaire contre l'héparanase. Selon l'invention, l'immunogène est l'héparanase ou un fragment de celle-ci, cet immunogène étant, de préférence, une cellule présentant un antigène (APC), telle qu'une cellule dendritique (DC) affichant l'héparanase ou un fragment de celle-ci sur sa surface. L'invention concerne également des compositions contenant ledit immunogène.
CA002453566A 2001-07-13 2002-07-10 Methode et composition permettant d'inhiber l'activite de l'heparanase Abandoned CA2453566A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30544601P 2001-07-13 2001-07-13
US60/305,446 2001-07-13
US35755302P 2002-02-15 2002-02-15
US60/357,553 2002-02-15
PCT/US2002/021773 WO2003006645A2 (fr) 2001-07-13 2002-07-10 Methode et composition permettant d'inhiber l'activite de l'heparanase

Publications (1)

Publication Number Publication Date
CA2453566A1 true CA2453566A1 (fr) 2003-01-23

Family

ID=26974593

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002453566A Abandoned CA2453566A1 (fr) 2001-07-13 2002-07-10 Methode et composition permettant d'inhiber l'activite de l'heparanase

Country Status (4)

Country Link
EP (1) EP1417304A4 (fr)
JP (1) JP2005521379A (fr)
CA (1) CA2453566A1 (fr)
WO (1) WO2003006645A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1479764A1 (fr) * 2003-05-19 2004-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Peptides derives de Heparanas pour la vaccination des patients cancereux
ES2251289B1 (es) 2004-02-27 2007-07-01 Bioiberica, S.A. Nuevo uso terapeutico de un grupo de polisacaridos sulfatados.
BRPI0910342A2 (pt) * 2008-03-31 2016-04-12 Shiseido Co Ltd preparação oral, preparação para injeção, preparação para a pele, uso externo, e método cosmético para prevenção e correção de rugas
US20180110799A1 (en) * 2014-09-02 2018-04-26 The Children's Hospital Of Philadelphia Compositions and Methods for the Inhibition of Chondrogenesis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968822A (en) * 1997-09-02 1999-10-19 Pecker; Iris Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
CN1280613A (zh) * 1997-10-28 2001-01-17 澳大利亚国立大学 编码哺乳动物内切葡糖醛酸糖苷酶的分离的核酸分子及其应用
WO2000052178A1 (fr) * 1999-03-01 2000-09-08 Insight Strategy & Marketing Ltd. Polynucleotide codant pour un polypeptide ayant une activite d'heparanase et expression de ce polynucleotide dans des cellules genetiquement modifiees
DE19955803A1 (de) * 1999-11-19 2001-05-23 Knoll Ag Verwendung von Heparanase-Inhibitoren zur Behandlung von Hersinsuffizienz

Also Published As

Publication number Publication date
WO2003006645A2 (fr) 2003-01-23
WO2003006645A3 (fr) 2003-07-24
EP1417304A2 (fr) 2004-05-12
EP1417304A4 (fr) 2005-11-23
JP2005521379A (ja) 2005-07-21

Similar Documents

Publication Publication Date Title
EP3394248B1 (fr) Composition de cellules dendritiques
US20170224777A1 (en) Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
US10888603B2 (en) Methods of treating cancer cells expressing tumor-associated integrins
KR19980703453A (ko) 악성 종양의 예방 또는 치료용의 ＨＥＲ-２/ｎｅｕ 단백질의세포내 도메인
US20220289865A1 (en) Anti-cancer peptide
KR20190126798A (ko) 당뇨병 치료를 위한 펩티드 및 방법
TW202043255A (zh) 具增進氧化還原酶基序之免疫原肽
KR20210090203A (ko) 또 다른 약리학적 활성제와 조합된 지속 작용성 인터류킨-15 수용체 효현제
KR20140116054A (ko) 다발성 경화증의 치료를 위한 ａｐｃ-매개 관용 유도
US10576145B2 (en) CD200 inhibitors and methods of use thereof
CA2453566A1 (fr) Methode et composition permettant d'inhiber l'activite de l'heparanase
US20020164318A1 (en) Cell lines and vectors for stimulation of an immune response to a differentiation antigen stimulated by an altered antigen
US20040247577A1 (en) Method and composition for inhibiting heparanase activity
AU782853B2 (en) Methods for preventing or attenuating pathoangiogenic conditions
US20090221804A1 (en) GBS Toxin Receptor Compositions and Methods of Use
KR20180088458A (ko) 암의 치료를 위한 mica/b 알파 3 도메인의 백신접종
US8609614B2 (en) GBS toxin receptor compositions and methods of use
KR101699567B1 (ko) ＪｕｎＢ의 발현 또는 활성 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
US20050053613A1 (en) Enhanced immunization and suppression of oral tolerance
WO2008142483A2 (fr) Compositions vaccinales et procédés d'utilisation de celles-ci
LEN Induction of anti-tumor response by dendritic cell-based vaccination

Legal Events

Date Code Title Description
FZDE Dead